The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective

The sodium-glucose transporter 2 inhibitors (SGLT2i) are a relatively new class of medication used in the management of type 2 diabetes. Recent clinical trials and research have demonstrated this class’s effectiveness in treating heart failure, since they reduce the risk of cardiovascular events, hospitalization, and mortality. The mechanism by which they do so is unclear; however, SGLT2i inhibit the tubular reabsorption of glucose, lowering the interstitial volume. This mechanism leads to a reduction in blood pressure and an improvement of endothelial function. As a result, improvements in hospitalization and mortality rate have been shown. In this review, we focus on the primary outcome of the clinical trials designed to investigate the effect of SGLT2i in heart failure, regardless of patients’ diabetic status. Furthermore, we compare the various SGLT2i regarding their risk reduction to investigate their potential as a treatment option for patients with reduced ejection fraction and preserved ejection fraction.

[1]  A. Khodir,et al.  A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: Role of oxidative stress, gut microbiota, and PPARγ activation. , 2022, European journal of pharmacology.

[2]  J. Badimón,et al.  SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction , 2022, Cardiovascular Drugs and Therapy.

[3]  Dabin Pan,et al.  Dapagliflozin Improves Diabetic Cardiomyopathy by Modulating the Akt/mTOR Signaling Pathway , 2022, BioMed research international.

[4]  F. Gao,et al.  Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis , 2022, Frontiers in Cardiovascular Medicine.

[5]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[6]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[7]  Sanjiv J. Shah,et al.  Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. , 2022, JACC. Heart failure.

[8]  P. Ponikowski,et al.  The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.

[9]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[10]  Sanjiv J. Shah,et al.  The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial , 2021, Nature Medicine.

[11]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[12]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[13]  Seok‐Min Kang,et al.  Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment , 2021, Korean circulation journal.

[14]  P. Mather,et al.  The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction , 2021, Therapeutic advances in cardiovascular disease.

[15]  W. Rottbauer,et al.  Spen deficiency interferes with Connexin 43 expression and leads to heart failure in zebrafish. , 2021, Journal of molecular and cellular cardiology.

[16]  W. Aronow.  Faculty Opinions recommendation of Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[17]  Haider Alkhateeb,et al.  Updates in pharmacotherapy of heart failure with reduced ejection fraction , 2020, Annals of translational medicine.

[18]  B. Zinman,et al.  Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. , 2020, The lancet. Diabetes & endocrinology.

[19]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[20]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[21]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[22]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[23]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[24]  J. McMurray,et al.  Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF , 2020, European journal of heart failure.

[25]  J. Januzzi,et al.  Heart Failure With Reduced Ejection Fraction: A Review. , 2020, JAMA.

[26]  P. Ponikowski,et al.  Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.

[27]  S. Verma,et al.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors , 2020, JACC. Basic to translational science.

[28]  L. Maier,et al.  Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. , 2020, Cardiovascular research.

[29]  C. Fonseca,et al.  Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential , 2020, Cardiovascular Drugs and Therapy.

[30]  Deepak L. Bhatt,et al.  Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. , 2019, Circulation.

[31]  A. Levin,et al.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.

[32]  S. Verma,et al.  SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects , 2019, Journal of the American Heart Association.

[33]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[34]  G. Filippatos,et al.  Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial , 2019, European journal of heart failure.

[35]  C. Wójcik,et al.  Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors , 2019, Current Cardiology Reports.

[36]  Andy Y Lee,et al.  Class effects of SGLT2 inhibitors on cardiorenal outcomes , 2019, Cardiovascular Diabetology.

[37]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[38]  G. Filippatos,et al.  Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial , 2019, European journal of heart failure.

[39]  K. Mahaffey,et al.  Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. , 2019, Circulation.

[40]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. , 2019, Circulation.

[41]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[42]  H. Bøtker,et al.  Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients , 2019, Circulation.

[43]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[44]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[45]  J. Tamargo.  Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments , 2018, European cardiology.

[46]  D. Loo,et al.  Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2 , 2018, Diabetologia.

[47]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[48]  V. Vallon,et al.  Development of SGLT1 and SGLT2 inhibitors , 2018, Diabetologia.

[49]  Andy Y Lee,et al.  Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. , 2018, Reviews in cardiovascular medicine.

[50]  P. A. Crawford,et al.  Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin , 2018, Diabetes, obesity & metabolism.

[51]  Dongli Tian,et al.  Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials , 2018, Diabetes, obesity & metabolism.

[52]  R. Coronel,et al.  Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation , 2017, Diabetologia.

[53]  S. Verma,et al.  Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure , 2017, JACC. Basic to translational science.

[54]  S. Azar,et al.  Antidiabetic medications in patients with heart failure. , 2017, Minerva endocrinologica.

[55]  R. DeFronzo,et al.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition , 2017, Nature Reviews Nephrology.

[56]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[57]  P. Lapuerta,et al.  Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes , 2015, Diabetes Care.

[58]  T. Heise,et al.  Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus , 2014, Diabetes, obesity & metabolism.

[59]  J. D. de Bakker,et al.  Reduced heterogeneous expression of Cx43 results in decreased Nav1.5 expression and reduced sodium current that accounts for arrhythmia vulnerability in conditional Cx43 knockout mice. , 2012, Heart rhythm.

[60]  C. Pollock,et al.  Glucose handling by the kidney. , 2011, Kidney international. Supplement.

[61]  M. Pfister,et al.  Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus , 2009, Clinical pharmacology and therapeutics.

[62]  G. Paolisso,et al.  Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. , 1991, Metabolism: clinical and experimental.

[63]  W. Kannel,et al.  Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.